A Comprehensive Self-Management Program With Diet Education Does Not Alter Microbiome Characteristics in Women With Irritable Bowel Syndrome.
cognitive behavioral therapy
gastrointestinal microbiome
irritable bowel syndrome
quality of life
self-management
Journal
Biological research for nursing
ISSN: 1552-4175
Titre abrégé: Biol Res Nurs
Pays: United States
ID NLM: 9815758
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
pubmed:
9
1
2021
medline:
28
9
2021
entrez:
8
1
2021
Statut:
ppublish
Résumé
Changes in diet and lifestyle factors are frequently recommended for persons with irritable bowel syndrome (IBS). It is unknown whether these recommendations alter the gut microbiome and/or whether baseline microbiome predicts improvement in symptoms and quality of life following treatment. Therefore, the purpose of this study was to explore if baseline gut microbiome composition predicted response to a Comprehensive Self-Management (CSM) intervention and if the intervention resulted in a different gut microbiome composition compared to usual care. Individuals aged 18-70 years with IBS symptoms ≥6 months were recruited using convenience sampling. Individuals were excluded if medication use or comorbidities would influence symptoms or microbiome. Participants completed a baseline assessment and were randomized into the eight-session CSM intervention which included dietary education and cognitive behavioral therapy versus usual care. Questionnaires included demographics, quality of life, and symptom diaries. Fecal samples were collected at baseline and 3-month post-randomization for 16S rRNA-based microbiome analysis. Within the CSM intervention group (n = 30), Shannon diversity, richness, and beta diversity measures at baseline did not predict benefit from the CSM intervention at 3 months, as measured by change in abdominal pain and quality of life. Based on both alpha and beta diversity, the change from baseline to follow-up microbiome bacterial taxa did not differ between CSM (n = 25) and usual care (n = 25). Baseline microbiome does not predict symptom improvement with CSM intervention. We do not find evidence that the CSM intervention influences gut microbiome diversity or composition over the course of 3 months.
Sections du résumé
BACKGROUND AND PURPOSE
Changes in diet and lifestyle factors are frequently recommended for persons with irritable bowel syndrome (IBS). It is unknown whether these recommendations alter the gut microbiome and/or whether baseline microbiome predicts improvement in symptoms and quality of life following treatment. Therefore, the purpose of this study was to explore if baseline gut microbiome composition predicted response to a Comprehensive Self-Management (CSM) intervention and if the intervention resulted in a different gut microbiome composition compared to usual care.
METHODS
Individuals aged 18-70 years with IBS symptoms ≥6 months were recruited using convenience sampling. Individuals were excluded if medication use or comorbidities would influence symptoms or microbiome. Participants completed a baseline assessment and were randomized into the eight-session CSM intervention which included dietary education and cognitive behavioral therapy versus usual care. Questionnaires included demographics, quality of life, and symptom diaries. Fecal samples were collected at baseline and 3-month post-randomization for 16S rRNA-based microbiome analysis.
RESULTS
Within the CSM intervention group (n = 30), Shannon diversity, richness, and beta diversity measures at baseline did not predict benefit from the CSM intervention at 3 months, as measured by change in abdominal pain and quality of life. Based on both alpha and beta diversity, the change from baseline to follow-up microbiome bacterial taxa did not differ between CSM (n = 25) and usual care (n = 25).
CONCLUSIONS AND INFERENCES
Baseline microbiome does not predict symptom improvement with CSM intervention. We do not find evidence that the CSM intervention influences gut microbiome diversity or composition over the course of 3 months.
Identifiants
pubmed: 33412896
doi: 10.1177/1099800420984543
pmc: PMC8755949
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
471-480Subventions
Organisme : NINR NIH HHS
ID : R01 NR004142
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007742
Pays : United States
Références
Gastroenterol Nurs. 2011 Mar-Apr;34(2):108-16
pubmed: 21455043
Front Cell Infect Microbiol. 2017 Nov 30;7:489
pubmed: 29250490
Front Microbiol. 2019 Jun 10;10:1136
pubmed: 31244784
BMJ. 2009 Aug 27;339:b3154
pubmed: 19713235
Gastroenterology. 2018 Jul;155(1):47-57
pubmed: 29702118
Cell Mol Gastroenterol Hepatol. 2016 Dec 11;3(2):218-230
pubmed: 28275689
Transl Psychiatry. 2016 Nov 1;6(11):e939
pubmed: 27801892
J Manag Care Spec Pharm. 2014 Apr;20(4):382-90
pubmed: 24684643
Nutrients. 2019 May 22;11(5):
pubmed: 31121812
Brain Behav Immun. 2018 Oct;73:615-624
pubmed: 29990567
Gut. 2018 May;67(5):872-881
pubmed: 28416515
J Neurogastroenterol Motil. 2016 Jan 31;22(1):102-11
pubmed: 26459461
Psychosom Med. 2017 Oct;79(8):905-913
pubmed: 28661940
Am J Gastroenterol. 2009 Dec;104(12):3004-14
pubmed: 19690523
Eur J Gastroenterol Hepatol. 2012 Aug;24(8):950-7
pubmed: 22617366
Am J Gastroenterol. 2017 Jan;112(1):152-162
pubmed: 27845338
Aliment Pharmacol Ther. 2015 Aug;42(4):418-27
pubmed: 26104013
J Acad Nutr Diet. 2020 Apr;120(4):565-586
pubmed: 31473156
Yale J Biol Med. 2016 Sep 30;89(3):397-422
pubmed: 27698624
J Affect Disord. 2020 Apr 1;266:429-446
pubmed: 32056910
J Clin Med. 2020 Mar 04;9(3):
pubmed: 32143424
Behav Brain Res. 2015 Jan 15;277:32-48
pubmed: 25078296
Wien Med Wochenschr. 2018 Mar;168(3-4):62-66
pubmed: 28887729
Am J Hum Genet. 2015 May 7;96(5):797-807
pubmed: 25957468
Dig Dis Sci. 2020 Mar;65(3):829-839
pubmed: 32026278
Bioinformatics. 2019 Oct 1;35(19):3567-3575
pubmed: 30863868
J Physiol. 2018 Oct;596(20):4923-4944
pubmed: 30066368
Gut. 2017 Jun;66(6):1075-1082
pubmed: 26818616
Science. 2011 Oct 7;334(6052):105-8
pubmed: 21885731
Clin Gastroenterol Hepatol. 2017 May;15(5):712-719.e4
pubmed: 27080737
J Psychosom Res. 2019 Mar;118:73-82
pubmed: 30522750
J Neuroinflammation. 2020 Jan 17;17(1):25
pubmed: 31952509
Nat Microbiol. 2019 Apr;4(4):623-632
pubmed: 30718848
Adv Ther. 2018 Mar;35(3):289-310
pubmed: 29498019
Br J Health Psychol. 2017 Nov;22(4):701-736
pubmed: 28573818
Cell. 2020 Sep 17;182(6):1460-1473.e17
pubmed: 32916129
Psychopharmacology (Berl). 2019 May;236(5):1459-1470
pubmed: 30955108
Gut Liver. 2015 May 23;9(3):318-31
pubmed: 25918261
Gut. 2019 Sep;68(9):1613-1623
pubmed: 30971419
Dig Liver Dis. 2017 Apr;49(4):331-337
pubmed: 28179092
Gastroenterology. 2016 Feb 19;:
pubmed: 27144617
World J Gastroenterol. 2019 Feb 7;25(5):552-566
pubmed: 30774271
Aliment Pharmacol Ther. 2013 Feb;37(3):304-15
pubmed: 23205588
J Clin Gastroenterol. 2020 Feb;54(2):175-183
pubmed: 30148765
Front Nutr. 2019 Mar 29;6:33
pubmed: 30984765
J Agric Food Chem. 2019 Aug 21;67(33):9124-9138
pubmed: 30969768
Gastroenterology. 2015 Nov;149(6):1399-1407.e2
pubmed: 26255043
J Clin Gastroenterol. 2020 Jan;54(1):63-69
pubmed: 30575634
Aliment Pharmacol Ther. 1997 Jun;11(3):547-52
pubmed: 9218081
Clin Gastroenterol Hepatol. 2004 Jul;2(7):585-96
pubmed: 15224283
Psychol Med. 2018 May;48(7):1148-1156
pubmed: 28893330